{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:36:16Z","timestamp":1770748576269,"version":"3.50.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Second Century Fund Chulalongkorn University Thailand","award":["1"],"award-info":[{"award-number":["1"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Coronavirus disease (COVID-19) not only has a long-term effect on its survivors, it also affects their quality of life, including inducing depression as a possible manifestation of central nervous system disruption. Favipiravir shows promising efficacy as an antiviral drug for the treatment of COVID-19. However, its effect on the sequelae of COVID-19 has not been explored. Therefore, this study aims to assess the impact of Favipiravir and address the factors associated with post-COVID depression in Indonesia.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Method<\/jats:title><jats:p>This cohort study conducted a post-COVID-19 survey on Indonesian patients who were diagnosed by using real-time polymerase chain reaction (RT-PCR) and antigen tests until January 2022. An online questionnaire was distributed to obtain information on demographics, comorbidities, health behavior, symptoms, and treatment. The propensity technique was used to allocate the participants into the favipiravir and nonrecipient groups (1:1). The Patient Health Questionnaire-9 (PHQ-9) was used for outcome measurement. The cohort was followed up biweekly for 60 days after onset\/diagnosis to determine the occurrence of depression. Cox regression analysis with an adjusted odds ratio and 95% confidence interval was used to estimate the effect of favipiravir on post-COVID-19 depression.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>The data included the information of 712 participants, of whom 18.54% had depression within 60 days after onset\/diagnosis. Depression was higher in the nonrecipient group (21.06%) than in the favipiravir group (16.01%). After adjustment by other factors, favipiravir prescription was found to be associated with depression (aOR 0.488, 95% CI 0.339\u20130.701 p &lt; 0.001). In accordance with the PHQ-9 subset, favipiravir exerted a significant protective effect against depressive mood and loss of interest. However, patients living alone were prone to experiencing loss of interest (aOR 2.253, 95% CI 1.329\u20133.818, p = 0.003).<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>The data obtained in this preliminary survey suggested that favipiravir may be useful for preventing post-COVID depression. However, further study is needed. Moreover, the provision of mental health support, particularly to those who live alone, must be ensured.<\/jats:p><\/jats:sec><jats:sec id=\"sec005\"><jats:title>Trial registration<\/jats:title><jats:p>Registry<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05060562\" xlink:type=\"simple\">NCT05060562<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0279184","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T18:58:53Z","timestamp":1672426733000},"page":"e0279184","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-6764","authenticated-orcid":true,"given":"Bumi","family":"Herman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekachaeryanti","family":"Zain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhar","family":"Dzulhadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aye Chan","family":"Oo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Viwattanakulvanid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"pone.0279184.ref001","author":"World Health Organization","year":"2022","journal-title":"WHO coronavirus (COVID-19) dashboard, situation by region, country, territory, and area Geneva"},{"issue":"4","key":"pone.0279184.ref002","first-page":"304","article-title":"Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis.","volume":"130","author":"G Lippi","year":"2020","journal-title":"Polish Archives of Internal Medicine"},{"issue":"3","key":"pone.0279184.ref003","doi-asserted-by":"crossref","first-page":"e2103","DOI":"10.1002\/rmv.2103","article-title":"Clinical features of deaths in the novel coronavirus epidemic in China","volume":"30","author":"C. Leung","year":"2020","journal-title":"Reviews in Medical Virology"},{"issue":"30","key":"pone.0279184.ref004","doi-asserted-by":"crossref","first-page":"993","DOI":"10.15585\/mmwr.mm6930e1","article-title":"Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network\u2013United States, March-June 2020. MMWR","volume":"69","author":"MW Tenforde","year":"2020","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"4","key":"pone.0279184.ref005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/thoraxjnl-2020-216377","article-title":"Persistent symptoms 1.5\u20136 months after COVID-19 in nonhospitalised subjects: A population-based cohort study.","volume":"76","author":"K Stavem","year":"2021","journal-title":"Thorax"},{"key":"pone.0279184.ref006","article-title":"COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19","author":"Health NIf, 2. Er: CEJ, prevalence","year":"2020","journal-title":").(NG188)"},{"issue":"5","key":"pone.0279184.ref007","article-title":"Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): An integrative classification.","volume":"18","author":"C Fern\u00e1ndez-de-Las-Pe\u00f1as","year":"2021","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"1","key":"pone.0279184.ref008","doi-asserted-by":"crossref","first-page":"16144","DOI":"10.1038\/s41598-021-95565-8","article-title":"More than 50 long-term effects of COVID-19: A systematic review and meta-analysis.","volume":"11","author":"S Lopez-Leon","year":"2021","journal-title":"Scientific Reports."},{"key":"pone.0279184.ref009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-030-59261-5_19","article-title":"Depression, anxiety, and stress among patients with COVID-19: A cross-sectional study","volume":"1321","author":"MS Moayed","year":"2021","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"2","key":"pone.0279184.ref010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19","volume":"24","author":"J Meinhardt","year":"2021","journal-title":"Nature Neuroscience"},{"issue":"2","key":"pone.0279184.ref011","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: Bases for physiological regulation, disease states, and pharmacological interventions.","volume":"70","author":"MA Erickson","year":"2018","journal-title":"Pharmacological Reviews."},{"issue":"3","key":"pone.0279184.ref012","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-020-02190-2","article-title":"Microvascular injury and hypoxic damage: Emerging neuropathological signatures in COVID-19","volume":"140","author":"Z Jaunmuktane","year":"2020","journal-title":"Acta Neuropathologica"},{"key":"pone.0279184.ref013","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpsychires.2015.05.007","article-title":"Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies","volume":"68","author":"GZ R\u00e9us","year":"2015","journal-title":"Journal of Psychiatric Research"},{"key":"pone.0279184.ref014","doi-asserted-by":"crossref","first-page":"111308","DOI":"10.1016\/j.nut.2021.111308","article-title":"Altered tryptophan absorption and metabolism could underlie long-term symptoms in survivors of coronavirus disease 2019 (COVID-19).","volume":"90","author":"\u0130 Ero\u011flu","year":"2021","journal-title":"Nutrition"},{"issue":"10","key":"pone.0279184.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11100659","article-title":"SARS-CoV2 infection alters tryptophan catabolism and phospholipid metabolism","volume":"11","author":"G Kaur","year":"2021","journal-title":"Metabolites"},{"key":"pone.0279184.ref016","doi-asserted-by":"crossref","first-page":"1178646920936279","DOI":"10.1177\/1178646920936279","article-title":"Potential role of neuroactive tryptophan metabolites in central fatigue: Establishment of the fatigue circuit. International Journal of Tryptophan Research","volume":"13","author":"M. Yamashita","year":"2020","journal-title":"IJTR"},{"issue":"1","key":"pone.0279184.ref017","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/26895293.2020.1835741","article-title":"Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection.","volume":"13","author":"CNS Allen","year":"2020","journal-title":"All life."},{"key":"pone.0279184.ref018","doi-asserted-by":"crossref","first-page":"107702","DOI":"10.1016\/j.intimp.2021.107702","article-title":"Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial","volume":"97","author":"H Zhao","year":"2021","journal-title":"International Immunopharmacology"},{"issue":"1","key":"pone.0279184.ref019","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12879-021-06164-x","article-title":"Favipiravir for the treatment of patients with COVID-19: A systematic review and meta-analysis.","volume":"21","author":"T Manabe","year":"2021","journal-title":"BMC Infectious Diseases."},{"key":"pone.0279184.ref020","doi-asserted-by":"crossref","first-page":"103204","DOI":"10.1016\/j.ebiom.2020.103204","article-title":"Understanding the pharmacokinetics of favipiravir: Implications for treatment of influenza and COVID-19.","volume":"63","author":"MG Ison","year":"2021","journal-title":"EBiomedicine"},{"key":"pone.0279184.ref021","doi-asserted-by":"crossref","first-page":"108611","DOI":"10.1016\/j.clim.2020.108611","article-title":"Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients","volume":"221","author":"C Gao","year":"2020","journal-title":"Clinical Immunology"},{"key":"pone.0279184.ref022","volume-title":"Diagnostic testing for SARS-CoV-2","author":"World Health Organization","year":"2020"},{"issue":"9","key":"pone.0279184.ref023","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9091910","article-title":"Sensitivity of Rapid Antigen Testing and RT-PCR Performed on Nasopharyngeal Swabs versus Saliva Samples in COVID-19 Hospitalized Patients: Results of a Prospective Comparative Trial (RESTART).","volume":"9","author":"A Kritikos","year":"2021","journal-title":"Microorganisms"},{"key":"pone.0279184.ref024","author":"World Health Organization","year":"2021","journal-title":"Antigen-detection in the diagnosis of SARS-CoV-2 infection"},{"key":"pone.0279184.ref025","volume-title":"Criteria for releasing COVID-19 patients from isolation: Scientific brief; 2020","author":"O. World health","year":"2020"},{"issue":"7","key":"pone.0279184.ref026","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jiph.2020.06.005","article-title":"Rajkumar. Laboratory diagnosis of SARS-CoV-2 \u2013A review of current methods","volume":"13","author":"JP Mathuria","year":"2020","journal-title":"Journal of Infection and Public Health"},{"key":"pone.0279184.ref027","volume-title":"Guideline for COVID-19 treatment in Indonesia","author":"Health mo","year":"2021"},{"key":"pone.0279184.ref028","article-title":"Guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for COVID-19.","author":"Health MoP","year":"2021","journal-title":"Thailand: Department of Disease Control."},{"issue":"1","key":"pone.0279184.ref029","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1002\/ams2.664","article-title":"Japanese Rapid\/Living recommendations on drug management for COVID-19","volume":"8","author":"K Yamakawa","year":"2021","journal-title":"Acute Medicine and Surgery"},{"issue":"12","key":"pone.0279184.ref030","first-page":"e14938","article-title":"The safety profile of favipiravir in COVID-19 patients with severe renal impairment","volume":"75","author":"S G\u00f6k","year":"2021","journal-title":"International Journal of Clinical Practice"},{"issue":"2","key":"pone.0279184.ref031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir\u2013a potential treatment in the COVID-19 pandemic?","volume":"6","author":"V Pilkington","year":"2020","journal-title":"Journal of Virus Eradication"},{"issue":"9","key":"pone.0279184.ref032","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"K Kroenke","year":"2001","journal-title":"Journal of General Internal Medicine"},{"key":"pone.0279184.ref033","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fpsyt.2018.00450","article-title":"DSM-5 criteria and depression severity: Implications for clinical practice.","volume":"9","author":"JC Tolentino","year":"2018","journal-title":"Frontiers in Psychiatry"},{"issue":"1","key":"pone.0279184.ref034","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s43045-021-00112-w","article-title":"Assessment of new-onset depression and anxiety associated with COVID-19.","volume":"28","author":"E Hurissi","year":"2021","journal-title":"Middle East Current Psychiatry"},{"issue":"1","key":"pone.0279184.ref035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12888-020-02885-6","article-title":"The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital.","volume":"20","author":"Y Sun","year":"2020","journal-title":"BMC Psychiatry"},{"key":"pone.0279184.ref036","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jad.2018.02.037","article-title":"Assessment of depression before and after inpatient rehabilitation in COPD patients: Psychometric properties of the German version of the Patient Health Questionnaire (PHQ-9\/PHQ-2).","volume":"232","author":"M Schuler","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"pone.0279184.ref037","year":"2021","journal-title":"COVID-19 Distribution according to provinces"},{"key":"pone.0279184.ref038","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S287934","article-title":"Favipiravir use in COVID-19: Analysis of suspected adverse drug events reported in the WHO database.","volume":"13","author":"RJ Kaur","year":"2020","journal-title":"Infection and Drug Resistance."},{"issue":"3","key":"pone.0279184.ref039","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40495-020-00216-7","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"6","author":"R Wu","year":"2020","journal-title":"Current Pharmacology Reports"},{"key":"pone.0279184.ref040","article-title":"Anxiety and depression symptoms after COVID-19 infection: Results from the COVID Symptom Study app.","author":"K Klaser","year":"2021","journal-title":"medRxiv: The preprint server for health sciences."},{"issue":"6","key":"pone.0279184.ref041","doi-asserted-by":"crossref","first-page":"e19636","DOI":"10.2196\/19636","article-title":"Identification of symptoms prognostic of COVID-19 severity: Multivariate data analysis of a case series in Henan Province.","volume":"22","author":"J Li","year":"2020","journal-title":"Journal of Medical Internet Research."},{"issue":"8","key":"pone.0279184.ref042","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00259-020-05178-y","article-title":"The cerebral network of COVID-19-related encephalopathy: A longitudinal voxel-based 18F-FDG-PET study","volume":"48","author":"A Kas","year":"2021","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"7","key":"pone.0279184.ref043","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1007\/s00415-020-09866-5","article-title":"CNS penetration of potential anti-COVID-19 drugs","volume":"267","author":"PJ Richardson","year":"2020","journal-title":"Journal of Neurology"},{"issue":"1","key":"pone.0279184.ref044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/IJPSYM.IJPSYM_160_19","article-title":"Vitamin D and depression: A critical appraisal of the evidence and future directions","volume":"42","author":"V Menon","year":"2020","journal-title":"Indian Journal of Psychological Medicine"},{"key":"pone.0279184.ref045","doi-asserted-by":"crossref","first-page":"624559","DOI":"10.3389\/fpubh.2021.624559","article-title":"The impact of vitamin D level on COVID-19 infection: Systematic review and meta-analysis.","volume":"9","author":"A Teshome","year":"2021","journal-title":"Frontiers in Public Health"},{"key":"pone.0279184.ref046","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fphar.2017.00414","article-title":"The emerging role for zinc in depression and psychosis","volume":"8","author":"MA Petrilli","year":"2017","journal-title":"Frontiers in Pharmacology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T19:42:36Z","timestamp":1701632556000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279184"}},"subtitle":[],"editor":[{"given":"Pedro Vieira da Silva","family":"Magalhaes","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279184","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}